Trials / Recruiting
RecruitingNCT05585580
Second-line Treatment With Serplulimab, Lenvatinib, and Paclitaxel in Advanced Gastric Cancer After Prior Immunotherapy
Efficacy and Safety of Serplulimab, Lenvatinib, and Paclitaxel in the Treatment of Advanced Gastric or Gastroesophageal Junction Adenocarcinoma After First-line Immunotherapy: a Prospective, Single-armed Clinical Trial
- Status
- Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 59 (estimated)
- Sponsor
- Qilu Hospital of Shandong University · Academic / Other
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This is a prospective, single arm, multicenter phase II study to assess the effectiveness of Serplulimab, Lenvatinib and Paclitaxel in the treatment of advanced gastric or gastroesophageal junction adenocarcinoma after first-line immunotherapy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Serplulimab | 300mg d1 q3w |
| DRUG | Lenvatinib | 8mg po qd |
| DRUG | Paclitaxel/Paclitaxel-albumin/Paclitaxel liposome | 135\~175mg/m2 /260mg/m2/135-175mg/m2 d1 q3w |
Timeline
- Start date
- 2023-03-01
- Primary completion
- 2025-11-01
- Completion
- 2026-11-01
- First posted
- 2022-10-19
- Last updated
- 2025-01-07
Locations
7 sites across 1 country: China
Source: ClinicalTrials.gov record NCT05585580. Inclusion in this directory is not an endorsement.